Warning Letter — JW Nutritional LLC
The FDA Center for Drug Evaluation and Research (CDER) issued a warning letter to JW Nutritional LLC following an inspection and regulatory review.
JW Nutritional LLC, and potentially third-party clients for whom they provide contract manufacturing services for products classified as drugs by the FDA.
The involvement of CDER rather than just the Center for Food Safety and Applied Nutrition (CFSAN) suggests that the FDA has identified products being marketed or manufactured as drugs without appropriate approvals or adherence to drug CGMPs. This implies significant compliance risks regarding product labeling, site registration, and manufacturing rigor.
Quality and Regulatory teams should conduct an immediate gap analysis of product classifications to ensure no marketed items meet the CDER definition of a drug. Review all manufacturing protocols for adherence to drug CGMP if such products are identified.
FDA Warning Letter issued to: JW Nutritional LLC. 04/15/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jw-nutritional-llc-722096-04152026
Open in openFDA / FDA.gov